ESSA Pharma rises on collaboration with Johnson & Johnson

ESSA Pharma

12/04/2023 12:40

** ESSA Pharma Inc's shares  EPIX.O  up 10.3% at $3.22
before the bell
    ** Drug developer enters collaboration with Johnson &
Johnson  JNJ.N  to develop EPIX's drug in combination with JNJ's
drugs as a treatment for patients with prostate cancer 
    ** Under the agreement, EPIX to sponsor and conduct
early-stage studies evaluating the safety of the drug when
administered in combination with JNJ's prostate drugs
apalutamide or abiraterone acetate plus prednisone 
    ** JNJ will supply apalutamide and abiraterone acetate
    ** EPIX to retain the rights over its prostate drug
candidate
    ** As of last close, EPIX was up ~16% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))